Skip to main content

Risques de cancer après exposition au DES

  • Chapter
  • 266 Accesses

Abstrait

L’action carcinogène du DES a été démontrée au niveau du tractus génital (seinsovaires-endomètre) de certaines espèces animales (1) (52 IGR). Le DES est assimilé à un cocarcinogène dont l’évolution vers l’apparition d’un cancer est liée à l’existence d’autres facteurs de risque: facteurs hormonaux péripubertaires déficience du système immunitaire, hypersensibilisation à l’action des virus Human papillomavirus (HPV)), mais aussi virus de l’herpès HSV2 (2) (2 IGR).

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Newbold RR, Mc Lachlan JA (1982) Vaginal adenosis and adenocarcinoma in mice exposed prenatally or neonatally to diethylstilbestrol. Cancer res 42: 2003–11

    PubMed  CAS  Google Scholar 

  2. Adam E, Kaufman RH, Adler-storthz K et al. (1985) A prospective study of association of herpes simplex virus and human papillomavirus infection with cervical neoplasia in women exposed to diethylstilbestrol in utero. Int J Cancer 35: 19–26

    Article  PubMed  CAS  Google Scholar 

  3. Herbst AL, Scully RE (1970) Adenocarcinoma of the vagina in adolescence. Cancer 25: 745–57

    Article  PubMed  CAS  Google Scholar 

  4. Herbst AL, Ulfelder H, Poskanzer DC (1971) Adenocarcinoma of the vagina associationn of maternal stilbestroltherapy with tumor appareance in young women. N Engl J Med 284: 878–81

    PubMed  CAS  Google Scholar 

  5. Herbst AL, Robboy SJ, Scully RE, Poskanzer DC (1974) Clear cell adenocarcinoma of the vagina and cervix in girls: analysis of 170 registry cases. Am J Obstet Gynecol 119: 713–24

    PubMed  CAS  Google Scholar 

  6. Melnick S, Cole P, Ander Sond, Herbst AL (1987) Rates and risks of diethylstilbestrol related clear cell adenocarcinoma of the vagina and cervix. N Engl J Med 316: 514–6

    PubMed  CAS  Google Scholar 

  7. Herbst AL, Anderson S, Hubby MM et al. (1986) Risk factors for the development of diethylstilbestrol-associated clear cell adenocarcinoma: a case-control study. Am J Obstet Gynecol 154: 814–22

    PubMed  CAS  Google Scholar 

  8. Gerbaulet A, Charmeau L, Haie-Meder C et al. (1993) L’adénocarcinome à cellules claires du col et du vagin de la jeune fille: DES syndrome. Possibilité de traitement conservateur. Bull Cancer/Radiother 80: 291–305 Elsevier, Paris

    Google Scholar 

  9. Herbst AL, Norusis MJ, Rosenow PJ et al. (1979) An analisis of 346 cases of clear cell adenocarcinoma of the vagina and cervix with emphasis on recurrence and survival. Gynecol Oncol 7: 111–22

    Article  PubMed  CAS  Google Scholar 

  10. LM LU DM Sciubba GI Gallia et al. (2007) Diethylstilbestrol (DES) induced clear adenocarcinoma of the vagina metastasing to the brain. Gynecologic Oncology 105: 273–6

    Article  Google Scholar 

  11. Brochure du ministère de la Solidarité, de la Santé et de la Protection sociale. Exposition au DES in utero

    Google Scholar 

  12. Cabau A (1991) Dépistage du cancer du vagin et du col chez les femmes exposées in utero au Distilbène in les enfants du distilbène B. Blanc Arnette ed p. 25–31

    Google Scholar 

  13. Hicks M, Piver HS (1992) Conservative surgery plus adjuvant therapy post vulvovaginal rhabdomyosarcoma, diethylstilbestrol clear cell adenocarcinoma of the vaginal and unilateral germ cell tumors of the ovary. Obstet Gynecol Clin North Am 19(1): 219–33

    PubMed  CAS  Google Scholar 

  14. Abu-Rustun NR, Wsu DA Lavin et al. (2005) Pediatric radical abdominal tractelectomy for cervical clear cell carcinoma Novel Surgical approch. Gynecolocic Oncology 97: 296–300

    Article  Google Scholar 

  15. RY Mc Nall, Nowieki PD, Million B et al. (2004) Adenocarcinoma of the cervix and vagina in pediatric patients, Pediatric Blood and Cancer 43(3): 289–94

    Article  Google Scholar 

  16. Mathews KS, Nummum TM, Conner MC, Bernes M (2007) Fertility sparing radical abdominal tractelectomy for clear cell adenocarcinoma of the upper vagina: a case report. Gynecologic Oncology in press.

    Google Scholar 

  17. Wharton JT, Rutledge FN, Gallager JS, Fletcher G (1975) Treatment of clear cell adenocarcinoma in young females. Obstet Gynecol 45: 365–8

    PubMed  CAS  Google Scholar 

  18. Ch Haie-Meder (2007) Peut-on envisager un traitement conservateur dans les adénocarcinomes à cellules claires post distilbèlne Marseille 26–27 octobre 7e colloque HAP

    Google Scholar 

  19. Touboul E, Lefranc JP, Deniaud-Alexandre E, Tranbaloc P (2001) Tumeurs du vagin et lésions apparentées. Adénocarcinome à cellules claires du vagin Encycl Méd Chir, Gynécologie, 530-A-10, 13 p.

    Google Scholar 

  20. Verloop J, Reakus MA, Van Leewen FE (2000) Prevalence of gynecologic cancer in women exposed to diethylstilbestrol in utero. N Engl J Med 342: 1838–9

    Article  PubMed  CAS  Google Scholar 

  21. Hatch EE, Herbst AL, Hoover RW et al. (2001) Incidence of squamous neoplasia of the cervix and vagina in women exposed prenatally to diethylstilbestrol (United States) Cancer Causes Control 12: 837–45

    Article  PubMed  CAS  Google Scholar 

  22. Keller C, Nauda R, Shannon RI et al. (2001) Concurrent primaris of vaginal clear cell adenocarcinoma and endometrial adenocarcinoma in a 39 years old women with in utero diethylstilbestrol exposure. Int J Gynecol Cancer 11: 247–50

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Agostini, A., Blanc, B., Lazard, A., Mulfinger, C. (2007). Risques de cancer après exposition au DES. In: Le Distilbène® trente ans après. Springer, Paris. https://doi.org/10.1007/978-2-287-73307-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-73307-9_9

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-73306-2

  • Online ISBN: 978-2-287-73307-9

Publish with us

Policies and ethics